parkinson's disease FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 4 parkinson's disease drugs. No FDA approvals recorded yet.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| ARV-102 | ARVN | — | — |
| envudeucitinib (ESK-001) | ALMS | small_molecule | — |
| rexaceract | GANX | — | — |
| Juvmo (tavapadon) | ABBV | — | — |
Upcoming catalysts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| 2026Year disclosed | ARV-102 | ARVN | Interim readout | Parkinson's disease | Scheduled | SEC Form 8-K |
| 1H 2027Half-year disclosed | envudeucitinib (ESK-001) | ALMS | Trial start | Parkinson's disease | Scheduled | SEC 8-K Exhibit 99.1 |
| Q1 2027Quarter disclosed | rexaceract | GANX | Trial start | Parkinson's disease | Scheduled | SEC 8-K Exhibit 99.1 |
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Q3 2026Quarter disclosed | rexaceract | GANX | Trial start | Parkinson's disease | Scheduled | SEC Form 10-Q |
| October 31, 2025 | Juvmo (tavapadon) | ABBV | NDA/BLA submission | Parkinson's disease | Completed | SEC 8-K Exhibit 99.1 |
| February 11, 2025 | ARV-102 | ARVN | Trial start | Parkinson's disease | Completed | SEC 8-K Exhibit 99.1 |
| January 10, 2025 | ARV-102 | ARVN | Trial start | Parkinson's disease | Completed | SEC Form 8-K |
All indications · Approval rates by indication
Questions
What parkinson's disease drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.